Background: Retinoids can reverse neoplastic lesions and prevent second primary tumors in the aerodigestive tract. These effects are thought to be mediated by nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), each receptor group including three subtypes (␣, ␤, and ␥). Previously, we found that RAR␤ expression was suppressed in lung cancer. In this study, we investigated whether expression of RAR␤ is modulated by chemopreventive intervention. Methods: Using in situ hybridization, we analyzed RAR␤ messenger RNA (mRNA) expression in bronchial biopsy specimens from heavy smokers, at baseline and after 6 months of treatment with 13-cis-retinoic acid (13-cis-RA) or placebo. Since we had previously detected RAR␤ expression in 90% of bronchial specimens from nonsmokers, we considered loss of RAR␤ mRNA expression in at least one of six biopsy specimens at baseline in this study to be aberrant. Results: RAR␤ mRNA expression was aberrant in 30 (85.7%) of 35 subjects in the 13-cis-RA group and in 24 (72.7%) of 33 subjects in the placebo group. After 6 months of 13-cis-RA treatment, the number of subjects who were RAR␤ positive in all six biopsy specimens increased from five of 35 to 13 of 35 (2.6-fold), so that the percentage of individuals with aberrant RAR␤ expression decreased to 62.9% (22 of 35), which represents a statistically significant difference from baseline expression (two-sided P = .01). In the placebo group, no statistically significant difference in RAR␤ expression was observed between baseline and 6 months. RAR␤ expression was not related to current smoking status or reversal of squamous metaplasia.
Lung cancer is the most common neoplasia worldwide (1) . As the leading cause of cancer death in the United States, lung cancer accounts for 28.6% of all cancer mortality and 7% of all deaths. It has been estimated that there were 171 500 new cases and 160 100 deaths from lung cancers in the United States in 1998 (2) . Lung cancer incidence is increasing in both men and women, and the mortality from it has surpassed that of breast cancer in women and of prostate cancer in men. Unfortunately, the overall 5-year survival rate is under 14%, despite advances in a variety of therapeutic modalities, including surgery, radiotherapy, and chemotherapy (1, 2) . Therefore, the development of new strategies for the prevention and treatment of lung cancer is urgently needed. One possible approach is chemoprevention, an intervention into the carcinogenesis process prior to the development of a locally invasive cancer (3) . Among the chemopreventive agents examined for effects on lung cancer, retinoids-including retinoic acid (RA)-appear to have the potential for chemoprevention of upper aerodigestive tract cancers (3) (4) (5) .
Vitamin A deficiency has been associated with bronchial metaplasia and increased lung cancer incidence (4, 5) . Retinoids regulate differentiation of airway epithelium in vitro (6) and suppress carcinogenesis in animal models of lung cancer (5, 7) . These effects of retinoids are thought to be mediated by nuclear retinoid receptors, which belong to the steroid/thyroid hormone superfamily. Like other members of this family, these receptors are ligand-activated, DNA-binding, trans-activating, transcription-modulating proteins. Two types of receptor have been identified: retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Each type includes three subtypes of RAR (␣, ␤, and ␥) and of RXR (␣, ␤, and ␥), with distinct amino-and carboxyl-terminal domains (8, 9) . Each subtype is thought to regulate the expression of distinct genes (8, 9) .
Aberrant expression of the nuclear retinoid receptors may result in an abrogated retinoid signaling pathway. Indeed, we (10) and others (11) (12) (13) (14) have demonstrated that RAR␤ expression is suppressed in both lung cancer tissues and cell lines, and this finding suggested that the decreased expression of this receptor is associated with lung carcinogenesis. However, RAR␤ expression in bronchial epithelium from heavy smokers has not been studied, nor was the effect on smokers of treatment with retinoids. Therefore, in this study, we used bronchial biopsy specimens from chronic smokers before and after treatment with 13-cis-RA or placebo (15) to evaluate RAR␤ expression and its modulation by treatment.
MATERIALS AND METHODS

Surgical Specimens
This retrospective study used tissue specimens that were available from a previous clinical trial conducted at The University of Texas M. D. Anderson Cancer Center, Houston (15) In this trial, 152 smokers were evaluated prospectively with bronchoscopy, and biopsy specimens were obtained from six predetermined anatomic sites located in the bronchus of each lobe plus the main carina of each subject. Subjects with dysplasia and/or a metaplasia index of greater than 15% were randomly assigned to receive either 1 mg/kg body weight of 13-cis-RA (isotretinoin provided by Hoffmann-La Roche Inc., Nutley, NJ) or placebo daily for 6 months. Of the 86 subjects, 41 were randomly assigned to the 13-cis-RA and 45 to the placebo group. Only 69 of the subjects were re-evaluated after a second bronchoscopy, with six biopsies performed at the completion of treatment to determine the metaplasia index, whereas the rest of the subjects did not complete the planned 6-month treatment because of various reasons, including refusal of treatment, loss to followup, toxic effects, and intercurrent illness (15) .
Bronchial biopsy specimens available for analysis of retinoid receptors in this study were obtained at baseline and after 6 months of treatment from 68 patients (specimens from the 69th patient were used up in another study), 35 of whom received 13-cis-RA and 33 of whom received placebo (15) . The specimens were fixed in 10% neutral formalin and embedded in paraffin at the Department of Pathology, The University of Texas M. D. Anderson Cancer Center. All of the specimens were cut into 4-mthick sections and one section was stained with hematoxylin-eosin for pathologic diagnosis, whereas the other consecutive sections were processed for retinoid receptor analysis by use of messenger RNA (mRNA) in situ hybridization technique that we described previously (16) .
In Situ Hybridization
A nonradioactive, in situ hybridization technique by use of digoxigenin-labeled antisense riboprobes or RAR␤ and RXR␣ was used to analyze nuclear retinoid receptors in formalin-fixed, paraffinembedded tissue sections as described in detail elsewhere (16) . The quality and specificity of the digoxigenin-labeled probes were determined with northern blotting, and the specificity of the binding of antisense riboprobes was verified by use of sense probes as controls (16) . To exclude any potential bias in the scoring of the RAR␤ expression, the hybridization procedure was done on samples that were coded so that the person who performed the analysis did not know whether the samples were from treated subjects or from the placebo group and whether they were obtained at baseline or at 6 months. The stained sections were reviewed and scored by use of an Olympus Microscope (Olympus America, Melville, NY).
Statistical Analysis
RAR␤ expression was measured in each of the six prespecified biopsy sites for each patient. Because the loss of RAR␤ expression is an abnormal event, we considered a patient as having an aberrant RAR␤ expression status if at least one of the six sites has lost RAR␤. All of the analyses were performed with each subject serving as the unit of analysis. Measures of RAR␤ and RXR␣ expression were assigned as positive or negative staining only. The McNemar test (17) was performed to determine the change in the aberrant RAR␤ expression before and after treatment. The method of generalized estimating equations with binary outcome and logistic link was applied to the data to compare change in the aberrant RAR␤ between the treatment groups. Analysis of variance was used to examine whether the reduction in metaplasia index is related to changes in RAR␤ status. All reported P values were two-sided. A test was considered statistically significant when P<.05.
RESULTS
The characteristics of subjects from whom specimens were available for this study are shown in Table 1 . Sections from six sites in the lungs of each case subject were placed on two glass slides for in situ hybridization to detect RAR␤, and adjacent sections were used to detect RXR␣. We found the latter receptor to be ubiquitous in lung and to be expressed in both normal and malignant lung epithelia (10) . We used it here as a control for the presence of undegraded RNA in a section to exclude false-negative data in the RAR␤ analysis in the adjacent section.
Representative examples of the in situ hybridization results are shown in Fig. 1 . The presence of receptor mRNA is indicated by purple staining of the cytoplasm of cells in biopsy sections incubated with antisense riboprobe. Normal bronchial epithelium from nonsmokers was available from a previous study (10) and was positive for RAR␤, as shown in Fig. 1 , A (upper left panel), whereas no RAR␤ mRNA was detected in a section of a bronchial biopsy taken at baseline from a smoker enrolled in the clinical trial (Fig.  1, A, middle left panel) . In contrast, RAR␤ was detected in a section of a biopsy taken from the same patient after 6 months of 13-cis-RA treatment (Fig. 1, A , bottom left panel). Biopsy specimens taken both at baseline and after placebo treatment were negative for RAR␤ (Fig.  1 , B, upper and lower panels, respectively). All specimens were positive for RXR␣ mRNA, indicating that degradation of mRNA could not account for the lack of staining with RAR␤ antisense probes. Sense RAR␤ riboprobes did not stain the sections (data not shown), indicating that the staining with antisense riboprobes was specific.
In previous studies (10, 18, 19) with visually identifiable, nonmalignant oral lesions, head and neck cancers, and lung cancers, we usually collected a single biopsy specimen per subject at baseline and another after treatment. Therefore, it was straightforward in such a study to classify a subject as being either positive or negative for RAR␤ expression. However, in this study, we collected bronchial tissue biopsy specimens from six different loci in the bronchial tree per subject, both at baseline and after treatment, and the analyses of individual biopsy specimens in the same subject did not always give the same results. Because our previous studies have demonstrated that normal bronchial epithelial tissues from more than 90% of nonsmoker's lungs were positive for RAR␤ mRNA (10), we considered a subject to have an aberrant RAR␤ expression if even one of six biopsy specimens was negative. Table 2 shows the results of the RAR␤ analyses. Aberrant RAR␤ expression was detected at baseline in 30 (85.7%) of 35 subjects in the 13-cis-RA group and in 24 (72.7%) of 33 subjects in the placebo group. For an unknown reason, although the subjects in the clinical trial (15) were randomly assigned to receive either placebo or 13-cis-RA, the latter group had a slightly higher percentage of aberrant RAR␤ expression at baseline compared with the former group. The difference between the two groups was not statistically significant (P ‫ס‬ .19).
After 6 months of 13-cis-RA treatment, the number of RAR␤-positive subjects (in whom all six biopsy specimens were positive for RAR␤) increased 2.6-fold (from five of 35 to 13 of 35). In contrast, in the placebo group, the number of RAR␤-positive subjects increased by only 1.1-fold (from nine of 33 to 10 of 33) ( Table 2 ). When the data were analyzed as changes in aberrant RAR␤, the percentage of subjects with an aberrant RAR␤ expression in the 13-cis-RA group decreased by 26.6% (from 85.7% at baseline to 62.9% at 6 months), and the change was statistically significant (P ‫ס‬ .01). In contrast, in the placebo group, the percentage of subjects with aberrant RAR␤ expression was reduced by only 4.1% (from 72.7% to 69.7% ), and there was no statistically significant difference in RAR␤ expression between baseline and 6 months ( Table 2 ). The difference in the change in RAR␤ expression between the 13-cis-RA group and the placebo group was compared with the use of the generalized estimating equations methods and was found not to be statistically significant (P ‫ס‬ .09). All specimens expressed RXR␣ at baseline and after treatment with either placebo or 13-cis-RA (data not shown). Sixteen subjects quit smoking at 6 months, whereas the remaining 52 subjects continued to smoke. The transition from aberrant to normal RAR␤ expression from baseline to 6 months was observed in two of the quitters and in seven (13.5%) of the persistent smokers. RAR␤ expression was not related to smoking status change at 6 months (P ‫ס‬ .52).
The change in RAR␤ expression was also not associated with the reversal of squamous metaplasia. The decrease in metaplasia index (95% bootstrap biascorrected accelerated percentile interval; n ‫ס‬ number of subjects) was 8.8 (1.9, 15.1; n ‫ס‬ 40), 7.6 (-5.3, 17.8; n ‫ס‬ 14), 8.8 (−5.9, 37.7; n ‫ס‬ 5), and 1.7 (−16.9, 33.6; n ‫ס‬ 9) among subjects with (+, +), (+, −), (−, +), or (−, −) aberrant RAR␤ at baseline and at 6 months, respectively. The difference was not statistically significant (P ‫ס‬ .90).
There was no association between the presence or absence of metaplasia at baseline and the expression of RAR␤ at baseline or the increase in RAR␤ after 6 months. For example, RAR␤ was increased in 34 (54.0%) of 63 sites that did not have metaplasia at baseline (histologically normal) and in 26 (70.3%) of 37 sites that had metaplasia at baseline (chisquared P ‫ס‬ .11).
DISCUSSION
In this study, we have demonstrated for the first time to our knowledge that RAR␤ expression is suppressed in biopsy specimens of bronchial epithelium from chronic smokers who were selected for the presence of dysplasia or metaplasia and that the receptor's expression increases after a 6-month treatment with 13-cis-RA in vivo. Because of the limited number of samples, the difference in the degree of increased RAR␤ expression between the 13-cis-RA group and the placebo group (26.6% versus 4.1%) is only marginally significant (P ‫ס‬ .09). It is noteworthy that, when we analyzed the data after considering a subject to be RAR␤ positive if even one of the six biopsy specimens was positive, then the P value of treatment difference in increased expression of RAR␤ was .02 instead of .09. However, we did not choose the classification of RAR␤ status of a subject to show the best result; instead, we have chosen it on the basis of the biologic reasoning that RAR␤ positivity is the normal state. Therefore, a loss of RAR␤ expression in even one biopsy specimen should classify the subject as having an aberrant RAR␤ expression.
An increase in RAR␤ expression was not associated with a reduction in the bronchial metaplasia index or with smoking cessation. The present findings-and our previous data on receptor expression in non-small-cell lung cancers (10)-are reminiscent of our previous observations in oral nonmalignant lesions (18) and head and neck cancers (19) , in that the decrease in RAR␤ expression occurred at early stages of carcinogenesis and could be reversed in some cases by 13-cis-RA treatment.
We used in situ hybridization for RAR␤ analysis because antibodies ob- tained from commercial and other sources appeared to cross-react with several protein bands on western blotting of lung cancer cell lines and normal bronchial epithelial cells (unpublished data).
Loss of RAR␤ mRNA expression has been observed in a variety of lung cancer cell lines (11) (12) (13) (14) , and it has been suggested that this loss may contribute to lung carcinogenesis. A potential role for RAR␤ in the suppression of lung cancer development has been further supported by the reports on the loss of tumorigenicity in nude mice by human lung cancer cells expressing a transfected RAR␤ (20) and the observation that transgenic mice expressing antisense RAR␤ 2 developed lung cancer (21) . The selective suppression of RAR␤ expression may be related to the process of malignant transformation in the lung (10) (11) (12) (13) (14) 20, 21) and may lead to resistance to growth inhibition by RA (12, 14, 22) . The loss of RAR␤ expression in the bronchial epithelium may be related to aberrations in the retinoidsignaling pathway because of changes in co-activators (9) or in other receptors, such as nuclear receptor 77 (nur77) or chicken ovalbumin upstream promotertranscription factor (22) .
The mechanism by which RAR␤ expression is increased in biopsy specimens from subjects treated with 13-cis-RA is not clear; it may be due to restoration of a more normal phenotype to the abnormal epithelium by the retinoid, induction of RAR␤ by activation of the RA response element in the RAR␤ promoter (8, 9) , or elimination of RAR␤-negative cells and their replacement by normal RAR␤-positive cells during the 6-month treatment with 13-cis-RA. The reason why 13-cis-RA treatment did not increase RAR␤ expression in all of the samples is not known. It is possible that in some subjects, the RAR␤-negative cells have severe defects in retinoid signaling that prevent even pharmacologic levels of retinoid from inducing RAR␤. Studies with lung cancer cell lines (14, 22) have demonstrated defects in induction of RAR␤.
Intermediate biomarkers are needed to evaluate the end point of chemoprevention (23) . Bronchial metaplasia is one of the earliest and reversible changes reflecting chronic irritation (cigarette smoking) or vitamin A deficiency (24, 25) . Previous studies (22, (25) (26) (27) suggested the use of bronchial metaplasia as a biomarker in lung cancer chemoprevention, but this marker has not been validated or shown to be associated with long-term cancer development. Furthermore, complete reversal of squamous metaplasia was noted in both placebo and 13-cis-RA groups (15) . In both groups, smoking cessation resulted in statistically significant declines in the extent of squamous metaplasia, whereas no statistically significant change in metaplasia index was found among those who continued to smoke. Thus, 13-cis-RA had no effect on squamous metaplasia, a candidate intermediate end point of bronchial carcinogenesis.
On the basis of our previous (10) and present studies, we propose to use RAR␤ as an intermediate biomarker for lung cancer chemoprevention trials, especially when retinoids are used as the chemopreventive agents, because its expression is suppressed in the field of carcinogenesis and is increased by 13-cis-RA in a fashion that is independent of squamous metaplasia and cigarette smoking status. Because of the limited sample size of this study, the full potential of using RAR␤ in chemoprevention trials needs to be validated by larger prospective studies in the future. *RAR ‫ס‬ retinoic acid receptor; 13-cis-RA ‫ס‬ 13-cis-retinoic acid (isotretinoin). †Percent of reduction in aberrant RAR␤ from baseline to 6 months was 4.1% and 26.6% for the placebo and 13-cis-RA groups, respectively. Two-sided P value for testing the change between groups was .09 by use of the method of generalized estimating equations. P<.05 was considered statistically significant.
‡In the placebo group, the aberrant RAR␤ was found at baseline and at 6 months in 24 (72.7%) of 33 subjects and in 23 (69.7%) of 33 subjects, respectively. The change was not statistically significant (the McNemar test; two-sided P ‫ס‬ .74).
§In the 13-cis-RA group, the aberrant RAR␤ was found at baseline and at 6 months in 30 (85.7%) of 35 subjects and in 22 (62.9%) of 35 subjects, respectively. The change was statistically significant (the McNemar test; two-sided P ‫ס‬ .01).
